Sequana Medical N.V.

SEQUA

BE0974340722

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 10:57:13 2024-04-26 am EDT			5-day change	1st Jan Change
1.39 ^EUR	-0.71%		-3.47%	-65.25%

Apr. 03	Sequana Medical Announces Strong Data from DSR Proof-of-Concept Studies in Heart Failure Published in European Journal of Heart Failure	CI
Mar. 28	Sequana Medical NV Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director

November 10, 2023 at 12:00 pm EST

Sequana Medical NV announced the appointment of Ids van der Weij as non-executive director of the Company.

Latest news about Sequana Medical N.V.

Sequana Medical Announces Strong Data from DSR Proof-of-Concept Studies in Heart Failure Published in European Journal of Heart Failure	Apr. 03	CI
Sequana Medical NV Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Sequana Medical NV Announces Three Month Follow-Up Data from MOJAVE Non- Randomized Cohort Confirming Significant Improvement in Diuretic Response and Virtual Elimination of Loop Diuretics Following DSR Therapy	Mar. 25	CI
Sequana Medical Raises EUR11.5 Million via Share Placement	Mar. 21	MT
Sequana Medical's Premarket Application for Alfapump Accepted by US FDA; Shares Rise	Jan. 29	MT
Sequana Medical Receives New US Reimbursement Codes for Alfapump System	Jan. 03	MT
Belgium's Sequana Medical Seeks US FDA Premarket Approval for Liver Ascites Treatment Device	Dec. 28	MT
Sequana Medical NV Announces Positive Data from Non- Randomized Cohort in US Phase 1/2a MOJAVE Study of DSR® 2.0 for Treatment of Heart Failure	Nov. 29	CI
Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director	Nov. 10	CI
Certain Shares of Sequana Medical NV are subject to a Lock-Up Agreement Ending on 22-OCT-2023.	23-10-21	CI
Transcript : Sequana Medical NV - Special Call	23-10-19
Sequana Medical NV Announces Initial Positive Data from MOJAVE, a US Phase 1/2A Study of DSR 2.0 for Treatment of Heart Failure through Breaking Vicious Cycle of Cardiorenal Syndrome	23-10-18	CI
Sequana Medical NV Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-14	CI
Transcript : Sequana Medical NV, H1 2023 Earnings Call, Sep 14, 2023	23-09-14
Belgium’s Sequana Medical Enrolls First Patient in Early-stage Trial for Treatment of Chronic Heart Failure	23-07-10	MT
Sequana Medical NV Announces First Patient Enrolled in Mojave, a US Randomized Controlled Phase 1/2a Study of DSR 2.0 for Treatment of Compostive Heart Failure	23-07-10	CI
Sequana Medical NV Announces Completion of 1,000th Alfapump Implant	23-07-06	CI
Sequana Medical NV Appoints Kenneth Macleod as Non-Executive Director	23-06-26	CI
Transcript : Sequana Medical NV - Special Call	23-06-21
Sequana Medical Secures US FDA Clearance for Investigational New Drug Application	23-05-02	MT
Belgium's Sequana Medical Raises EUR16 Million to Advance Clinical Programs	23-04-25	MT
Sequana Medical NV announced a financing transaction	23-04-23	CI
Sequana Medical NV Announces Submission of Investigational New Drug Application for DSR® 2.0 for Treatment of Congestive Heart Failure	23-04-03	CI
Sequana Medical Receives US, Chinese Patents for Direct Sodium Removal Program	23-03-22	MT
Sequana Medical Announces Positive Results from Chihuahua, Phase 1 Clinical Trial of Second-Generation DSR Product for Congestive Heart Failure	23-03-01	CI

Sequana Medical N.V. is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump is a fully-implanted, wireless device that automatically pumps fluid from the abdomen into the bladder, where it is removed naturally through urination. The alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and has been granted breakthrough device designation by the US FDA with a North American pivotal study underway. DSR is a novel approach to manage sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity. The alfapump DSR® combines DSR therapy with the proven alfapump platform and is in clinical development as potential treatment for decompensated heart failure patients.

Sector

Biotechnology & Medical Research

Calendar

2024-05-22 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Sequana Medical N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.39 EUR

Average target price

5.967 EUR

Spread / Average Target

+329.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SEQUANA MEDICAL N.V.	-65.25%	53.29M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research